Introduction International guidelines endorse the screening of patients for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and Chlamydia trachomatis before assisted reproductive techniques (ART). At present no such guidelines exists in South Africa. At the Reproductive and Endocrine Unit (referred to as “the Unit”) of Steve Biko Academic Hospital, all patients with unknown HIV status are counselled and a blood sample is collected during the initial visit for automated laboratory based HIV screening. These HIV results are not available before semen samples are processed. Furthermore, patients are not screened for HBV, HCV and Chlamydia trachomatis. Couples attending the Unit are of a low to middle socio-economic status and experience financial constraints. Moreover, automated laboratory based assays are expensive to perform. Rapid testing is a cost effective and practical method from screening patients, with a 20–30 minute result turnover time. Until screening at the Unit is improved, the possible identification of semen characteristics that could indicate HIV infection would be a useful tool. Materials and Methods The following rapid point-of-care assays were evaluated: Determine® HIV-1/2 combo test (n=100), Determine® HBsAg test (n=100), DIAQUICK HCV kit (n=74), and the DIAQUICK Chlamydia trachomatis kit (n=30). For profiling, parameters from a basic semen analysis of HIV-positive males (n=60) were compared with HIV-negative males (n=60). Information pertaining to CD4 count, antiretroviral treatment and plasma viral load of HIV-positive males were analysed. Results From all patients included in the study, 8% tested positive for HIV. The risk of a female being HIV-positive was 3.73 times higher than for males. In the pilot study to explore rapid testing for HBV and HCV, 1% and 1.4% of patients tested positive respectively. When testing for Chlamydia trachomatis 31.3% of females, but no males tested positive. Comparing semen profiles, no significant differences were found between samples from HIV positive and negative males or between HIV positive males categorised by CD4 cell count (p>0.05). For the HIV-positive group with a detectable plasma HIV viral load (>40 copies/ml), a significant difference was observed in the semen viscosity (p=0.0460). Significant differences were noted in the sperm motility (immotile sperm p=0.0456, progressive sperm p=0.0192) of patients receiving antiretroviral (ARV) therapy. Discussion and Conclusion The use of rapid testing is an acceptable and feasible option for improving current screening protocols at the Unit. The absence of definite alterations in the semen characteristics of HIV-positive men further motivates the need for a simpler, point-of-care screening protocol. The prevalence of HBV was lower than that reported in the general population of South Africa and further investigation is needed. Although the sample size was small, HCV prevalence was similar to that of the general population. One third of females tested positive for Chlamydia trachomatis. The methodology used was possibly not appropriate for males. This study highlighted the need for guidelines that address the specialised needs of ART clinics in resource-limited and developing countries with a high HIV prevalence. / Dissertation (MSc)--University of Pretoria, 2013. / gm2014 / Obstetrics and Gynaecology / unrestricted

Η πολυλειτουργική πρωτεΐνη core του ιού της ηπατίτιδας C (HCV) εμπλέκεται στην ανάπτυξη ηπατοκυτταρικού καρκινώματος (HCC) που προκαλείται από τον ιό της ηπατίτιδας C, αλλά ο μηχανισμός με τον οποίο συμβαίνει αυτό δεν είναι κατανοητός. Η ενεργοποίηση του μονοπατιού Wnt/ β-κατενίνη, παίζει ένα σημαντικό ρόλο στην ανάπτυξη ηπατοκυττταρικού καρκίνου, και τροποποιείται από την πρωτεΐνη core του ιού της ηπατίτιδας C. Ο ιός της ηπατίτιδας C χαρακτηρίζεται από εκτεταμένη γενετική ποικιλομορφία και διαφορετικά κλινικά δείγματα διαφέρουν όσον αφορά την μολυσματικότητα τους και την παθογένεια που προκαλούν. Σκοπός αυτής της μελέτης είναι να καθοριστεί ο ρόλος της γενετικής ποικιλομορφίας της πρωτεΐνης HCV core στην ενεργοποίηση του μονοπατιού Wnt/ β-κατενίνη και να μελετηθεί ο μοριακός μηχανισμός με τον οποίο η πρωτεΐνη HCV core ρυθμίζει την ενεργοποίηση αυτή. Η ενεργότητα του μονοπατιού Wnt/β-κατενίνη μελετήθηκε σε HEK 293T και Huh 7.5 κυτταρικές σειρές που εκφράζουν παροδικά τις πρωτεΐνες core των γενοτύπων 1a, 1b, 3a, 4a, 4f και από ένα μοναδικό δείγμα του γενοτύπου 1a που προέρχεται από έναν ασθενή από την Καμπότζη (1aCam). Μελέτες βασισμένες στη μέτρηση ενεργότητας της λουσιφεράσης, Western blot ανάλυση και qPCR, χρησιμοποιήθηκαν για την μέτρηση των επιπέδων έκφρασης γονιδίων και πρωτεϊνών. Βρέθηκε ότι η HCV core πρωτεΐνη ρυθμίζει θετικά την μεσολαβούμενη από τη β-κατενίνη Tcf-εξαρτώμενη ενεργότητα της λουσιφεράσης σε ένα γενοτυπο-εξαρτώμενο τρόπο. Σε συμφωνά με τα αποτελέσματα αυτά βρέθηκε ότι η πρωτεΐνη HCV core σταθεροποίει τα επίπεδα της β-κατενίνης, τόσο σε παροδικά μετασχηματισμένα κύτταρα, όσο και σε κύτταρα που μολύνονται με βακουλοϊούς που εκφράσουν τις πρωτεΐνες core των υποτύπων 4a και 4f. Τέλος, βρέθηκε ότι η πρωτεΐνη HCV core συμβάλει στην θετική ρύθμιση των γονιδίων c-myc, αξίνης και Tbx3, τα οποία είναι καθοδικά γονίδια στόχοι του μονοπατιού Wnt/β-κατενίνη και εμπλέκονται στην ανάπτυξη ηπατοκυτταρικού καρκινώματος. Συμπερασματικά, οι πρωτεΐνες HCV core διαφορετικών γενοτύπων του ιού ρυθμίζουν διαφορετικά το μονοπάτι σηματοδότησης Wnt/β-κατενίνη και η διαφορετική αυτή ρύθμιση μπορεί να σχετίζεται με ικανότητα των διαφόρων γενοτύπων του ιού της ηπατίτιδας C να επάγουν την ανάπτυξη ηπατοκυτταρικού καρκινώματος. / The multifunctional HCV core protein is implicated in the development of hepatocellular carcinoma (HCC) caused by HCV infection, but the underlying mechanism is not fully understood. Activation of the Wnt/ β-catenin pathway plays a major role in HCC and is modulated by the HCV core protein. HCV is characterized by extensive genetic diversity and different clinical isolates do vary in their infectivity and pathogenesis mainly due to variations in the structure/function relationships of individual viral proteins. The aim of this study is to determine the possible influence of genetic variability in HCV core protein in enhancing the Wnt/ β-catenin signaling activity and to elucidate the molecular mechanisms by which HCV core modulates activation of β-catenin. The Wnt/β-catenin activity was investigated in transiently transfected HEK 293T and Huh 7.5 cell lines transiently expressing HCV core proteins from HCV genotypes 1a, 1b, 4a, 4f and from a unique isolate of genotype 1a obtained from a Cambodian patient (1aCam). Luciferase-based reporter assay, Western blot, and qPCR, were used to measure gene and protein expression levels. We found that, HCV core protein upregulates β-catenin-mediated Tcf-dependent luciferase activity in a genotype specific manner. Consistent to these findings, HCV core stabilizes β-catenin levels. Finally, we showed that HCV core contributes to the upregulation of Tbx3 gene expression, a downstream target gene of Wnt/ β-catenin pathway contributing to HCC development. In conclusion, HCV core protein from different genotypes appears to differentially regulate the Wnt/β-catenin signaling pathway and this finding may contribute to different potential of HCV genotypes to induce HCC.

published_or_final_version / Psychology / Doctoral / Doctor of Philosophy

Hepatitis C virus (HCV) establishes a chronic infection in about 70% of infected individuals that is associated with the development of liver cirrhosis and hepatocellular carcinoma. The mechanisms by which HCV avoids clearance by the host immune response are not fully understood. The first aim of this project was to determine whether immune cell subsets could become infected by HCV in vitro. None of the haematopoietic subsets analysed expressed all of the required entry factors, CD81, SR-BI, claudin-1 and occludin. Also, PBMCs were not susceptible to infection with HCVpp and HCVcc expressing glycoproteins of hepatotropic strains. Infection by a supposedly lymphotropic strain (SB) was found to be inefficient. The second aim was to identify in vitro immunomodulatory effects of HCV on innate immune cells that may impact on the immune response activated in acute infection. Crosslinking of CD81 on NK cells by antibody was found to have a minor inhibitory effect on their activation via CD16, but CD81 crosslinking by viral particles had no detectable effect. In contrast to other viruses, HCVcc elicited very little interferon-α production by pDC. HCVcc also did not affect pDC or mDC responses to TLR ligation. Systemic cytokine and chemokine responses were analysed in subjects with primary acute HCV infection and in HCV-infected patients undergoing liver transplantation (LT). Interestingly, induction of systemic type I and type III interferon was not observed in either group. Marked perturbations in systemic cytokine and chemokine levels were detected in uninfected LT patients, precluding use of HCV-infected LT patients to study the innate immune response activated in response to acute viral replication. Together, these results suggest that HCV may principally evade innate immune cell responses by avoidance rather than impairment strategies.

Hepatitis C virus (HCV) is a major global pathogen that infects an estimated 170 million people worldwide, and for which currently no vaccine is available. HCV is a highly diverse viral pathogen and exists as 6 major genotypes sharing only 75% sequence homology; developing a vaccine that is cross-reactive between genotypes is a major challenge. Defining immune responses that target different HCV genotypes will facilitate pan-genotypic T cell vaccine development. HCV genotype 3 (gt3) is now the most common infecting genotype in the United Kingdom and large parts of Asia; however, data regarding the T cell antigenic targets of this genotype is very limited. In this thesis, HCV gt3 specific T cell targets were defined in acute, chronic and spontaneously resolved infection: in chronic gt3 infection, T cell responses were low in magnitude and narrowly focused in specificity, similar to those previously reported for gt1; in contrast, resolved infection was associated with a higher magnitude and broader specificity of CD4+ and CD8+ T cell responses across the genome. Overall, T cell specificity in gt3 infection was markedly different to that previously described for gt1, confirming that sequence differences between genotypes result in distinct immunological profiles. Previous work from our laboratory demonstrated that, though T cell responses induced by a potent T cell vaccine containing HCV gt1b non-structural regions do target epitopes dominant in natural infection, induced T cells show limited cross-reactivity against other genotypes. In this thesis, it was assessed whether T cells primed in natural gt3 infection are able to recognize viral sequence variants at dominant epitopes, which would make these potential targets in cross-reactive vaccine design. For seven gt3-specific T cell epitopes identified here as dominant, major sequence variability was observed within and between genotypes, and limited T cell cross-reactivity observed against identified viral variants. This suggests that regions frequently targeted in natural infection may not serve as attractive targets for cross-reactive vaccine design. These results informed the subsequent design of a cross-reactive vaccine based on fragments of HCV that are conserved between genotypes. A generic algorithm was developed to define viral regions conserved between major HCV genotypes (for 1a/1b, 1/3a, 1-6), and these were joined to form immunogens between 819 and 1543 AA long. Possible artificial, non-HCV epitopes formed by junctions were identified using online epitope prediction servers, and abrogated through the insertion of 2-6 amino acid linkers. To address the concern that conserved regions may not be immunogenic, epitopes described in natural HCV infection were mapped on HCV sequences, showing that conserved segments are well populated with epitopes; additionally, strong binding peptides were predicted for conserved segments using online epitope prediction programs, suggesting potential in vivo immunogenicity. In conclusion, HCV T cell specificity is distinct between genotypes, with limited T cell cross-reactivity between viral variants. Leading from this result, vaccine immunogens were designed entirely based on conserved viral regions. This work paves the way for future studies of novel HCV immunogens based on conserved viral segments between genotypes.

Le virus de l’hépatite C (HCV) est l’agent responsable de l’hépatite C, maladie qui touche environ 3% de lapopulation mondiale. Une des caractéristiques de cette infection est son évolution dans 60 à 90% des casvers des formes chroniques avec des complications sévères telles que la cirrhose et le carcinomehépatocellulaire. Un des handicaps majeurs de la recherche sur le HCV est l’absence de systèmes decultures in vitro efficaces et de modèles animaux adaptés car le HCV n’infecte que l’homme et le chimpanzé.l’anticorps D32.10. Pour cela, nous avons développé un test de cellbindinget nous avons montré quel’interaction des particules virales sériques (HCVsp) radiomarquées à l’Iode 125 avec les celluleshépatocytaires (Huh‐7 et HepaRG) est spécifique et saturable impliquant des sites de haute et faible affinité.De plus, l’anticorps D32.10 est capable d’inhiber spécifiquement et efficacement les interactions de hauteaffinité entre les HCVsp et les cellules HepaRG avec une IC50 ≤ 0,5 μg/ml. Nous avons mis en évidence quel’inhibition est plus efficace lorsque nous utilisons sélectivement une population de particules HCVenveloppées exprimant fortement E1E2. Récemment, nous avons développé un système d’infection originaldes cellules HepaRG qui sont des cellules progénitrices du foie par les HCVsp et avons montré quel’infection, la réplication et la propagation dépendent de l’état de prolifération/différenciation de cescellules. Nous avons aussi démontré que les particules virales produites dans ce système contiennent del’ARN viral, expriment les protéines d’enveloppe E1E2 et sont infectieuses. Des études préliminairesmontrent que l’anticorps D32.10 inhibe fortement l’infection (95% à 80% aux jours 14 et 21 aprèsinfection) vraisemblablement au niveau des étapes précoces du cycle viral.Dans un second temps, nous avons recherché la prévalence des anticorps de même spécificité que le D32.10(anti‐E1E2A,B) dans différents groupes de patients HCV positifs afin de déterminer leur significationbiologique. Par un test ELISA utilisant les peptides biotinylés E1, E2A et E2B dans la phase de capture, nousavons démontré que la réponse anticorps anti‐E1E2A,B était présente dans 90% des cas chez les patientsqui guérissent spontanément avec des titres élevées (≥ 1/1000). Cette réponse humorale est absente ourare (< 10%) chez les patients porteurs chroniques non traités ou non répondeurs aux traitementsantiviraux. Une étude longitudinale a été réalisée chez des patients non répondeurs ou répondeursdéveloppant une réponse virologique soutenue à une bithérapie standard, interféron pégylé plus ribavirine.L’analyse statistique des résultats a montré que les anticorps anti‐E1E2A,B pouvaient être prédictifs de laréponse au traitement avec une spécificité et une valeur prédictive positive de 100%.La convergence des résultats in vitro et in vivo supporte un rôle neutralisant de l’anticorps monoclonalD32.10, permettant d’envisager son utilisation en immunothérapie. / Hepatitis C Virus (HCV) is the major etiological agent of liver disease in the world with approximately180 million people who are seropositive. The majority (60‐90%) of infected individuals progressesto chronic hepatitis that increases their risk for developing cirrhosis and hepatocellular carcinoma.One of the major limitations of HCV research is the lack of efficient in vitro culture systems andappropriateanimal models. vitro direct cell‐binding assay and an infection system of the human HepaRG cell line were developedby using HCVsp. The HepaRG cells possess potent ability to acquire a mature hepatocyte phenotype.The E1E2‐specific mAb D32.10 was shown to inhibit efficiently and specifically high affinityinteractionsthrough glycosaminoglycans and the CD81 tetraspanin between HCVsp and HepaRGcells with an IC50 = 0.5 μg/ml. This inhibition was more efficient when E1E2‐positive envelopedHCVsp were used selectively for binding studies (IC50 < 0.5 μg/ml). Establishment of infection,replication and propagation of HCVsp were shown to depend on the proliferation/differentiationstage of HepaRG cells. Persistent HCV infection in HepaRG cells could be obtained with production ofE1E2/RNA(+) infectious HCV particles. Preliminary data showed a complete early inhibitory effect ofthe D32.10 mAb on virion RNA production in HepaRG culture supernatants (95% at D14 and 80% atD21 post‐infection).Furthermore, the detection of the anti‐E1E2/D32.10‐binding peptide antibodies during natural HCVinfection demonstrated significant prevalence (90%) of these antibodies: (1) in patients whorecovered spontaneously from HCV infection with high titers compared to patients with chronichepatitis C, and (2) in patients who are complete responders compared to non responders toantivirals. Kinetic analyses revealed that the anti‐E1E2/D32.10‐like humoral response appeared veryearly with high titers (≥ 1/1000) and was associated with complete virus eradication. The positiveand negative predictive values (ROC curve analysis) for achieving or not a sustained viral response toantiviral therapy are 100% and 86%, respectively, reflecting diagnostic accuracy. The anti‐E1E2/D32.10‐binding peptide antibodies may thus predict the outcome of HCV infection andrepresent a new relevant pronostic marker in serum for the HCV diagnosis.Convergence of in vitro and in vivo data strongly support the neutralizing activity of the D32.10 mAb,and thus immunotherapeutic potential of this unique anti‐E1E2 D32.10 mAb.

L'infection par le virus de l'hépatite C (HCV) reste aujourd'hui une cause majeure d'hépatite chronique, de cirrhose du foie et de carcinome hépatocellulaire. L'attachement cellulaire et l'entrée de HCV sont médiés par les protéines d'enveloppe E1 et E2. De nouveaux récepteurs ont été récemment identifiés mais l'entrée du virus dans les hépatocytes reste énigmatique et n'a jamais été visualisée. Nous avons tout d'abord caractérisé le modèle des pseudo-particules HCV (HCVpp) encryomicroscopie électronique en transmission (cryo-MET). Ce sont des particules sphériques de 100 nm de diamètre portant à leur surface E1 et E2. Nous avons ensuite visualisé l'entrée des HCVpp dans les hépatocytes en MET conventionnelle en utilisant des lignées d'hépatome et des hépatocytes primaires humains(PHH). Ces derniers maintiennent leur polarité en culture comme en témoigne la persistance de canalicules biliaires, tels que dans les hépatocytes natifs. Après synchronisation à 4°C avec les cellules, les HCVpp sont retrouvées liées aux prolongements cellulaires via des 'piliers', et sont ensuite internalisées à 37°C par endocytose dépendante de la clathrine. Ces 'piliers', actuellement en cours d'identification par immunomarquages, sont internalisés avec les HCVpp dans les hépatocytes au sein de vésicules de clathrine ; ce suivi est effectué par des approches de congélation haute pression et de tomographie électronique. Enfin, les évènements d'endocytose des HCVpp dans les PHH se sont avérés rares, avec une cinétique ralentie comparée aux lignées cellulaires. Ces études en MET soulignent l'importance d'utiliser un modèle cellulaire physiologique polarisé pour l'étude du mécanisme d'entrée de HCV. / Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Receptor recognition, cell binding and membrane fusion rely on HCV envelope proteins E1 and E2. New receptors were recently discovered; however HCV entry into hepatocytes remains largely unknown and has not yet been visualized. At first, we characterized HCV pseudoparticles (HCVpp) by cryo-transmission electron microscopy (cryo-TEM). They appeared as regular spherical structures of ca. 100-nm, with E1 and E2 at their surface. By conventional TEM, we then visualized HCVpp entry into hepatocytes, using hepatoma cells and primary human hepatocytes (PHH) as a more physiological cell model.PHH maintain their polarity in culture as attested by TEM observation of persistent bile canaliculi. At 4°C, viral particles were primarily found attached to microvilli at the cell surface via molecular bridges and, after warming to 37°C, they were internalized by endocytosis in clathrin-coated pits and vesicles. Using freeze substitution and electron tomographyapproaches, these bridges were found intimately surrounding HCVpp inside the clathrincoated vesicles, suggesting a concomitant internalization. The nature of these bridges is currently under investigation by immunogoldlabeling approaches. Finally, we reproducibly observed less HCVpp internalization events in PHH compared to hepatoma cells, and the kinetics of these events seemed delayed, probably due to PHH polarity. To conclude, ourTEM approach proved powerful to visualize HCV entry, and highlights the importance of studying a physiological cell model to understand HCV entry mechanism.

Le virus de l‘hépatite E (VHE) est endémique mondialement. Dans les pays en voie de développement, le VHE est une cause majeure d'hépatite aiguë et l'hépatite E est une maladie du péril fécal, transmise par la consommation d'eau contaminée. Le taux de mortalité de l'hépatite E aiguë en situation d'épidémie est estimé entre 0,2 et 4%. Dans les pays développés, l'hépatite E d'origine autochtone a émergé au début du XXIème siècle et un réservoir porcin à l'origine de transmissions zoonotiques du VHE a été établi. En 2008, pour la première fois, des formes chroniques de l'hépatite E ont été décrites révélant que le VHE était également une cause d'hépatite chronique et de cirrhose. Ces nouvelles formes d'hépatite E ont été rapportées chez des patients immunodéprimés pour transplantation d'organes solides, par le virus de l'immunodéficience humaine ou par des hémopathies malignes ou les traitements de ces hémopathies. Les travaux de cette Thèse ont eu pour objectifs de décrire les aspects cliniques puis épidémiologiques de l'hépatite E, d'étudier certains aspects immunologiques de l'hôte et certains aspects virologiques des VHE dans le but de comprendre les mécanismes conduisant au développement d'une hépatite E chronique dans la population des patients transplantés d'un rein suivis au CHU de Marseille. Nous avons décrit dans une étude rétrospective les caractéristiques et l'histoire naturelle de 16 infections autochtones diagnostiquées devant une hépatite inexpliquée. Nous avons décrit une évolution majoritairement chronique de l'hépatite E et son potentiel cirrhogène. / Hepatitis E virus (HEV) is endemic worldwide. In developing countries, HEV is a major cause of acute hepatitis and hepatitis E is a disease transmitted by the faecal-oral route through contaminated water. The estimated mortality rate of acute hepatitis E in the setting of outbreaks ranges from 0.2 to 4%. In developed countries, hepatitis E of autochthonous origin emerged at the beginning of twenty-first century and a porcine reservoir for HEV has been established that is a source for zoonotic transmission. In 2008, for the first time, chronic forms of hepatitis E have been reported showing that HEV was also a cause of chronic hepatitis and cirrhosis. These new forms of hepatitis E have been reported in immunocompromised patients due to solid organ transplantation, infection by human immunodeficiency virus, hematological malignancies or treatment of these malignancies. The objectives of this Thesis have been to describe the clinical and epidemiological features of hepatitis E, to examine some immunological aspects of the host and some virological aspects of HEV in order to understand the mechanisms leading to the development of chronic hepatitis E in the population of kidney transplant recipients followed at the University Hospital of Marseille. In a retrospective study, we described the characteristics and natural history of 16 HEV infections diagnosed in patients presenting with unexplained hepatitis. We described that hepatitis E progressed the most frequently towards chronicity and possibly towards liver cirrhosis. We showed that after dose reduction of immunosuppressants, more than half of the chronic infections resolved.

Dans les pays d’Afrique Sub-Saharienne et d’Asie du Sud-Est, l’infection chronique par le virus de l’hépatite B (VHB) et l’exposition à l’aflatoxine B1 (AFB1) ont un rôle synergique dans le développement du carcinome hépatocellulaire (CHC). Cependant les mécanismes impliqués ne sont pas élucidés à ce jour. Le VHB est un petit virus à ADN qui induit différentes maladies du foie allant du portage asymptomatique au CHC. L’AFB1 est une mycotoxine qui contamine la nourriture. Après activation en époxyde, elle forme des adduits à l’ADN puis des mutations, dont la mutation au codon 249 du gène suppresseur de tumeur TP53 (AGG → AGT, mutation R249S). Nous avons utilisé les caractéristiques uniques de la lignée cellulaire HepaRG pour étudier les interactions entre le VHB et l’AFB1 : ces cellules se différencient in vitro en hépatocytes qui métabolisent l’AFB1 et peuvent être infectés par le VHB. Nous avons montré que l’AFB1 induit une réponse de p53 dose-dépendante et agit comme un agent antiviral en réprimant la production de particules virales après 48h d’exposition. D’autre part, l’infection par le VHB n’a montré aucun effet sur la formation ou la réparation des adduits. De la réparation et de la prolifération cellulaire ont été observées suite au traitement à l’AFB1, suggérant la faisabilité de l’étude de mutations dans ce système, dont R249S. Ces résultats suggèrent que l’AFB1 atténue l’hépatite chronique tout en maintenant les hépatocytes sous intense pression mutagène, ce qui favoriserait la progression vers le CHC / In sub-Saharan Africa and South-East Asia, chronic infection by hepatitis B virus (HBV) and exposure to aflatoxin B1 (AFB1) play a synergic role in the development of hepatocellular carcinoma (HCC). However mechanisms are still largely unknown. HBV is a small DNA virus which induces different liver diseases from asymptomatic carriage to HCC. AFB1 is a mycotoxin which contaminates food. After activation into an epoxide, it forms DNA adducts and mutations, such as R249S mutation at codon 249 in tumor suppressor TP53 gene (AGG → AGT). We have taken advantage of the unique features of the cell line HepaRG to investigate interactions between both risk factors: cells differentiate in vitro into hepatocytes which metabolize AFB1 and can be infected by HBV. We have shown that AFB1 induces a dose-dependent p53 response and act as an antiviral agent by repressing production of HBV particles after 48 hours of exposure. Nevertheless HBV infection had no effect on adduct formation or repair. Moreover DNA synthesis activity associated to DNA repair and cell proliferation were observed following AFB1 treatment, suggesting the feasibility of mutation research in this model, especially R249S. Overall these results suggest that AFB1 may attenuate HBV chronic hepatitis while maintaining hepatocytes under intense mutagenic pressure, thus enhancing the progression towards HCC

Si la découverte récente de la souche virale JFH1, capable de réaliser un cycle viral complet en culture cellulaire, a permis de mieux caractériser le déroulement de l’infection du virus de l’hépatite C VHC, de nombreux aspects de la biologie du virus demeurent méconnus. Parmi ceux-ci, les mécanismes gouvernant l’encapsidation de l’ARN génomique viral au sein des particules restent à élucider. Cette thèse décrit la mise point d’un système de mobilisation hétérologue permettant l’analyse de l’interaction de la protéine de capside Core avec l’ARN viral. Ce système nous a permis d’identifier les régions de la protéine impliquées dans la liaison au génome viral, tout en autorisant son transfert dans des cellules naïves. Cette approche de mobilisation dépendante de la Core est complétée d’une étude de recrutement hétérologue basée sur la reconnaissance de l’ARN du phage MS2 avec la protéine de manteau Coat. Cette stratégie novatrice permet le recrutement efficace des ARNs marqués tout en autorisant leur localisation cellulaire. / The advent of infectious molecular clones of Hepatitis C virus (HCV) has unlocked the understanding of HCV life cycle. However, packaging of the genomic RNA, which is crucial to generate infectious viral particles, remains poorly understood. To study packaging in vivo, we developed a novel heterologous system to evaluate the interactions of HCV Core capside with viral RNA. This system allowed us to pinpoint Core domains involved in RNA binding, and package and transfer HCV RNA into a lentiviral vector. Aside from this Core dependent recruitment, we engineered retoviral vectors to trans-package MS2-tagged RNAs using MS2 Coat protein interaction. This system allowed us to efficiently recruit MS2-tagged replicons into naive cells and offers the opportunity to visualize HCV RNAs in Huh7.5 cells.